Race Oncology Ltd has released a press release.
RC220 Peripheral Infusion Safety Confirmed
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- RC220 Toxicology and Safety Pharmacology Studies Initiated
- Bisantrene cGMP API Manufacturing Completed at Laurus Labs
- Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells
- Race Board and Management Team Changes
- Race Strategic Update August 2023
Later from Racura Oncology
- Trading Halt
- Impressive Bisantrene Phase 2 AML Clinical Results
- RC220 Meets Quality Specifications
- Dr Daniel Tillett appointed CEO of Race Oncology
- Updated Strategy and Investor Presentation
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology